164 related articles for article (PubMed ID: 20406620)
21. Flaxseed alone or in combination with tamoxifen inhibits MCF-7 breast tumor growth in ovariectomized athymic mice with high circulating levels of estrogen.
Chen J; Power KA; Mann J; Cheng A; Thompson LU
Exp Biol Med (Maywood); 2007 Sep; 232(8):1071-80. PubMed ID: 17720953
[TBL] [Abstract][Full Text] [Related]
22. Tamoxifen induces p21WAF1 and p27KIP1 expression in estrogen receptor-negative lung cancer cells.
Lee TH; Chuang LY; Hung WC
Oncogene; 1999 Jul; 18(29):4269-74. PubMed ID: 10435640
[TBL] [Abstract][Full Text] [Related]
23. Investigation of elemene-induced reversal of tamoxifen resistance in MCF-7 cells through oestrogen receptor α (ERα) re-expression.
Zhang B; Zhang X; Tang B; Zheng P; Zhang Y
Breast Cancer Res Treat; 2012 Nov; 136(2):399-406. PubMed ID: 23053650
[TBL] [Abstract][Full Text] [Related]
24. Regulation of vitamin D receptor expression via estrogen-induced activation of the ERK 1/2 signaling pathway in colon and breast cancer cells.
Gilad LA; Bresler T; Gnainsky J; Smirnoff P; Schwartz B
J Endocrinol; 2005 Jun; 185(3):577-92. PubMed ID: 15930183
[TBL] [Abstract][Full Text] [Related]
25. p27(Kip1) induces quiescence and growth factor insensitivity in tamoxifen-treated breast cancer cells.
Carroll JS; Lynch DK; Swarbrick A; Renoir JM; Sarcevic B; Daly RJ; Musgrove EA; Sutherland RL
Cancer Res; 2003 Aug; 63(15):4322-6. PubMed ID: 12907598
[TBL] [Abstract][Full Text] [Related]
26. Leptin attenuates the anti-estrogen effect of tamoxifen in breast cancer.
Chen X; Zha X; Chen W; Zhu T; Qiu J; Røe OD; Li J; Wang Z; Yin Y
Biomed Pharmacother; 2013 Feb; 67(1):22-30. PubMed ID: 23199901
[TBL] [Abstract][Full Text] [Related]
27. G protein pathway suppressor 2 (GPS2) is a transcriptional corepressor important for estrogen receptor alpha-mediated transcriptional regulation.
Cheng X; Kao HY
J Biol Chem; 2009 Dec; 284(52):36395-36404. PubMed ID: 19858209
[TBL] [Abstract][Full Text] [Related]
28. Targeting of the adaptor protein Tab2 as a novel approach to revert tamoxifen resistance in breast cancer cells.
Cutrupi S; Reineri S; Panetto A; Grosso E; Caizzi L; Ricci L; Friard O; Agati S; Scatolini M; Chiorino G; Lykkesfeldt AE; De Bortoli M
Oncogene; 2012 Oct; 31(40):4353-61. PubMed ID: 22249258
[TBL] [Abstract][Full Text] [Related]
29. Elevated nuclear expression of the SMRT corepressor in breast cancer is associated with earlier tumor recurrence.
Smith CL; Migliaccio I; Chaubal V; Wu MF; Pace MC; Hartmaier R; Jiang S; Edwards DP; Gutiérrez MC; Hilsenbeck SG; Oesterreich S
Breast Cancer Res Treat; 2012 Nov; 136(1):253-65. PubMed ID: 23015261
[TBL] [Abstract][Full Text] [Related]
30. Genomic action of permanently charged tamoxifen derivatives via estrogen receptor-alpha.
Rivera-Guevara C; Pérez-Alvarez V; García-Becerra R; Ordaz-Rosado D; Morales-Ríos MS; Hernández-Gallegos E; Cooney AJ; Bravo-Gómez ME; Larrea F; Camacho J
Bioorg Med Chem; 2010 Aug; 18(15):5593-601. PubMed ID: 20621492
[TBL] [Abstract][Full Text] [Related]
31. Androgen receptor promotes tamoxifen agonist activity by activation of EGFR in ERα-positive breast cancer.
Ciupek A; Rechoum Y; Gu G; Gelsomino L; Beyer AR; Brusco L; Covington KR; Tsimelzon A; Fuqua SA
Breast Cancer Res Treat; 2015 Nov; 154(2):225-37. PubMed ID: 26487496
[TBL] [Abstract][Full Text] [Related]
32. Cooperative activation of cyclin D1 and progesterone receptor gene expression by the SRC-3 coactivator and SMRT corepressor.
Karmakar S; Gao T; Pace MC; Oesterreich S; Smith CL
Mol Endocrinol; 2010 Jun; 24(6):1187-202. PubMed ID: 20392877
[TBL] [Abstract][Full Text] [Related]
33. [Expression of ER alpha and SMRT in apoptosis of breast cancer cells induced by tamoxifen].
Zhao XH; Wang ZY; Li LL
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2008 May; 37(3):276-82. PubMed ID: 18546531
[TBL] [Abstract][Full Text] [Related]
34. ER-alpha36, a variant of ER-alpha, promotes tamoxifen agonist action in endometrial cancer cells via the MAPK/ERK and PI3K/Akt pathways.
Lin SL; Yan LY; Zhang XT; Yuan J; Li M; Qiao J; Wang ZY; Sun QY
PLoS One; 2010 Feb; 5(2):e9013. PubMed ID: 20126312
[TBL] [Abstract][Full Text] [Related]
35. CSNK1G2 differently sensitizes tamoxifen-induced decrease in PI3K/AKT/mTOR/S6K and ERK signaling according to the estrogen receptor existence in breast cancer cells.
Nguyen Hoang AT; Hoe KL; Lee SJ
PLoS One; 2021; 16(4):e0246264. PubMed ID: 33861751
[TBL] [Abstract][Full Text] [Related]
36. Identification of a negative regulatory surface within estrogen receptor alpha provides evidence in support of a role for corepressors in regulating cellular responses to agonists and antagonists.
Huang HJ; Norris JD; McDonnell DP
Mol Endocrinol; 2002 Aug; 16(8):1778-92. PubMed ID: 12145334
[TBL] [Abstract][Full Text] [Related]
37. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
38. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
[TBL] [Abstract][Full Text] [Related]
39. New approaches to the understanding of tamoxifen action and resistance.
Berstein LM; Zheng H; Yue W; Wang JP; Lykkesfeldt AE; Naftolin F; Harada H; Shanabrough M; Santen RJ
Endocr Relat Cancer; 2003 Jun; 10(2):267-77. PubMed ID: 12790788
[TBL] [Abstract][Full Text] [Related]
40. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
